Clinical trials: Platelet Transfusion Refractoriness (PTR)
Platelet Transfusion Refractoriness, Acute Leukemia in Remission
Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL
Alloimmune-mediated platelet transfusion refractoriness(PTR) was usually caused by repeated blood transfusions and pregnancy and accounts for about 20-25% of PTR patients.
- Trial name
- NCT04846439
- Testing
- CAR-T infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Platelet Transfusion Refractoriness
Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With PTR
The purpose of this study is to improve the platelet level of PTR patients; Prevent and improve bleeding; Help patients to successfully through the bone marrow suppression period after chemotherapy; Reduce the overall rate of PTR…
- Trial name
- NCT05761457
- Testing
- Cryopreserved autologous platelet transfusion
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Platelet Transfusion Refractoriness (PTR), Thrombocytopenia
The SOLID Platelet Study
Background: Platelets are cell fragments in the blood that help it clot. Some people get very low platelet counts during a disease or treatment. Low platelet counts can cause severe bleeding.
- Trial name
- NCT03712618
- Testing
- Platelet Transfusion - LONG Platelet Transfusion, Platelet Transfusion - SHORT Platelet Transfusion
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hematological Malignancies, Platelet Transfusion Refractoriness (PTR)
Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies
Platelet transfusion refractoriness (PTR) is a common complication in patients with hematological malignancies. It not only prolongs the duration of platelet transfusion dependence and significantly increases the risk of…
- Conditions
- Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA Antibodies
- Trial name
- AB-HLA-2026 (NCT07635511)
- Testing
- Acalabrutinib maleate, bortezomib, HLA-matched or crossmatched irradiated platelets
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University